Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Anovulation”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed1984

[Anovulation of hypothalamic origin. Treatment by pulsatile injection of hypothalamic gonadotropin releasing hormone].

In two patients with severe hypogonadotrophic hypogonadism intermittent pulsatile delivery of gonadotrophin hormone (LHRH) 5 to 20 micrograms every 90 minutes by means of the Zyklomat pump promptly resulted in ovulation and pregnancy. The comparative effectiveness of the intravenous and subcutaneous routes was evaluated by radioimmuno assay of LHRH in plasma. The pulsatile patterns of LH was satisfactory with both routes, but plasma levels of LHRH were about 7 times lower with the subcutaneous route. The dosage range (5-20 micrograms) of LHRH must be adjusted to the severity of the hypothalamic deficiency and to the route of administration. The use of the pump, the monitoring of ovulation and the indications for this type of treatment are discussed.

Adult↗
PubMed1984

[The effects of bromocriptine in normoprolactinemic anovulation and dysovulation: followed by pregnancy in 11 cases].

The authors report the results of a study of 40 patients with normal serum prolactin levels who were treated with bromocriptine for sterility secondary to ovulatory disturbances. This therapy restored normal ovulatory cycling in 62.5% of cases with subsequent pregnancy in 27.5% of cases, in particular in patients with primary infertility of long duration. The course of "latent" hyperprolactinemia (peak of TRH, repeated dosages of PRL) was discovered in only one out of two patients who responded to treatment. In patients with "non-latent" normal serum prolactin levels, bromocriptine's mechanism of action is not always clear.

Anovulation↗
PubMed1978

Anovulation and increased androgenic activity as breast cancer risk in women with fibrocystic disease of the breast.

The urine of 26 otherwise healthy women with fibrocystic disease of the breast was assayed by gas chromatography for testosterone and androstanediol (5alpha-androstane-3alpha, 17beta-diol), the major metabolite of dihydrotestosterone. The mean values for both androgens were significantly higher than in 18 normal women in the same age range. Sixteen of the 26 fibrocystic disease patients also had endometrial hyperplasia. Since the endometrial specimen was obtained in the premenstrual period, the presence of hyperplasia proved that the menstrual cycle in over two-thirds of the fibrocystic disease patients was nonovulatory.

Adult↗
PubMed1981

Incremental clomiphene therapy: a new method for treating persistent anovulation.

Thirty anovulatory patients, previously unresponsive to clomiphene citrate in standard dosage, were treated with a new incremental method of clomiphene therapy. Clomiphene was given continuously with dosage increments every 5 days, up to a maximum dose of 3750 mg, and ovarian response was monitored with urinary estrogen estimation and with ultrasound. Twenty-one patients (70%) ovulated on this regimen and 8 (27%) conceived; 6 patients who ovulated but did not conceive had other infertility factors. Clomiphene response was associated with a progressive rise in follicle-stimulating hormone, luteinizing hormone, and estrogen excretion; these parameters were unchanged in nonresponders. Side effects of treatment were minimal and only 1 case of hyperstimulation occurred. Preliminary testing with estrogen-amplified gonadotropin-releasing hormone did not differentiate responders from nonresponders. Incremental clomiphene treatment appears to be a less complicated alternative for patients who would otherwise require exogenous gonadotropin therapy.

Adult↗
PubMed1982

Menstrual cycle changes with marathon training: anovulation and short luteal phase.

Fourteen normal women (self-selected from 180 women enrolled) in a marathon training clinic kept basal body temperature (BBT), mileage, and weight records for 48 cycles before the marathon. Entry criteria were: Age 20-45, gynecologic age greater than 5 years, no hormone use, or weight change in 3 months. The women were 35.2 +/- 5.6 years in age, 22.6 +/- 5.1 years gynecologic age, runners of 4.1 +/- 2.5 years with premenstrual symptoms, previous pregnancy 4/14, no infertility and 2/14 remote amenorrhea. BBT records were obtained and analyzed by Vollman's criteria (1977). There was no weight loss. 32/48 cycles were biphasic but only 16 were normal in the length of the premenstrual phase (PreM = luteal, nl 10 - 16 d) with a mean of 11.1 +/- 1.2 days. The other 16 biphasic cycles had short PreM phase of 6.4 +/- 1.8 days. Monophasic (M = anovulatory) cycles occurred in 16/48 records. Cycles which were abnormal (Short PreM and M) differed only in that usual run length was longer (9.6 - 9.9 miles) than in normal cycles (7.9 +/- 2.4 miles). Marathon training may be associated with normal length but M and short PreM type cycles.

Adult↗
PubMedDate not supplied

Treatment of chronic anovulation and corpus luteum deficiency with epimestrol.

Ten patients presenting with anovulatory syndrome (AS, 4 patients), inadequate luteal phase (ILP, 3 patients) and short luteal phase (SLP, 3 patients) were treated with epimestrol for 29 cycles in total. The initial treatment was always 10 mg/day for 10 days followed by a modification of the daily dose and/or length of treatment needed. Ovulation was induced in all 4 AS patients with an adequate luteal phase (ALP) in 3 of them. In all other patients (with ILP and SLP) an ALP was induced; 2 of them became pregnant. No side-effects were reported.

Administration, Oral↗